NewcelX Ltd. files Form D for private placement raising $2.94 million
The Switzerland-based biotech, previously known as NLS Pharmaceutics Ltd., reported completing an equity and warrant offering to five investors.
SEC filing
Latest
2 stories
Monday, August 24
Friday, July 31
NewcelX prices $1.4 million private placement at 20% premium
The Zurich-based biopharmaceutical company will sell shares and warrants to fund its lead type 1 diabetes program after a recent FDA Pre-IND meeting.
SEC filing